.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A new Phase III clinical trial highlights the significant efficacy of Dupilumab for CRSwNP in Chinese adult patients. Researchers recently published these findings in the journal Allergy, demonstrating that this monoclonal antibody provides a robust solution for those with inadequately controlled disease. Chronic rhinosinusitis with nasal polyps (CRSwNP) severely impacts patient quality of life, yet many fail to respond to standard intranasal corticosteroids.
During the study, investigators randomized 63 patients to receive either dupilumab 300 mg every two weeks or a placebo. Importantly, all participants continued their daily intranasal corticosteroid therapy as an add-on treatment. After 24 weeks, the results showed a clear clinical benefit for the intervention group.
The trial met its primary endpoint, showing a significant reduction in the Nasal Polyp Score (NPS) with dupilumab compared to placebo. Furthermore, patients experienced substantial relief from nasal congestion, which is a common and distressing symptom. Additionally, objective tests revealed a marked improvement in the sense of smell. Patients also reported better overall health-related quality of life, as measured by the SNOT-22 score.
Regarding safety, the drug was well-tolerated among the Chinese cohort. The most common adverse events included nasopharyngitis and injection site reactions, which aligns with previous international studies. No new safety concerns emerged during the 24-week period. Therefore, these results reinforce the global evidence supporting biologics in managing type 2 inflammatory airway diseases. This trial provides crucial data specifically for the Asian population, where such evidence was previously limited.
The primary endpoint was the change from baseline in the nasal polyp score (NPS) at week 24. The results showed a significant improvement in the dupilumab group compared to the placebo group.
Common adverse events included nasopharyngitis and injection site reactions. These findings are consistent with the established safety profile of dupilumab in other global clinical trials.
Yes, the study demonstrated a significant improvement in the University of Pennsylvania Smell Identification Test (UPSIT) scores for patients receiving dupilumab compared to those on placebo.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Xian M et al. Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo-Controlled, Phase III Trial. Allergy. 2026 Jun 16. doi: 10.1111/all.70414. PMID: 42299713.
2. ClinicalTrials.gov. Dupilumab in Chinese Adult Participants With CRSwNP. NCT05878093. Available at: https://clinicaltrials.gov/study/NCT05878093.
3. Han JK, et al. Efficacy and Safety of Dupilumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Results From the Randomized Phase 3. Presented at the 2019 Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A Phase III trial confirms that Dupilumab significantly reduces nasal polyp scores and improves symptoms like congestion and smell in Chinese adults with severe CRSwNP. The treatment was well-tolerated with a safety profile consistent with previous studies, providing robust evidence for this population.
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
